Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6899274 | 0.96 | NR1H4 (0.48) | NR1H4PTPN1LMNAHTR1AADRA1D | |
| SCHEMBL6897555 | 0.95 | NR1H4 (0.50) | NR1H4PTPN1LMNAHTR1AADRA1D | |
| SCHEMBL8581492 | 0.85 | HTR1A (0.51) | NR1H4LMNAHTR1AADRA1DADRA1A | |
| SCHEMBL6762521 | 0.85 | NR1H4 (0.44) | NR1H4PTPN1LMNA | |
| SCHEMBL8585279 | 0.84 | NR1H4 (0.47) | NR1H4LMNAHTR1AADRA1DADRA1A | |
| SCHEMBL3987117 | 0.83 | PTPN1 (0.52) | PTPN1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL5778874 | 0.83 | PTPN1 (0.49) | PTPN1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL6899767 | 0.83 | NR1H4 (0.46) | NR1H4HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL8582404 | 0.83 | NR1H4 (0.46) | NR1H4HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL6807260 | 0.81 | NR1H4 (0.60) | NR1H4SMN1; SMN2MAPTTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198779-A1 | Heterocycle substituted diphenyl leukotriene antagonists | SAWYER JASON SCOTT (US) | 2004-10-07 | — | — | US | disclosed |
| US-6797723-B1 | Heterocycle substituted diphenyl leukotriene antagonists | ELI LILLY AND COMPANY | 2004-09-28 | — | — | US | disclosed |
| US-6673813-B2 | INHIBITING MEMBRANE TRANSPORT MEDIATED BY THE MULTIDRUG RESISTANCE ASSOCIATED PROTEIN MRP IN A PATIENT BY ADMINISTERING A COMPOUND HAVING AN AMPHIPHILIC ANION AND A MOLECULAR WEIGHT OF FROM 300 TO 950 DALTONS. | JEDLITSCHKY GABRIELE (DE) | 2004-01-06 | — | — | US | disclosed |
| CN-1387518-A | Heterocyclic substituted diphenyl leukotriene antagonists | LILLY CO ELI (US) | 2002-12-25 | — | — | CN | disclosed |
| EP-1263743-A1 | HETEROCYCLE SUBSTITUTED DIPHENYL LEUKOTRIENE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2002-12-11 | — | — | EP | disclosed |
| EP-1231939-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2002-08-21 | — | — | EP | disclosed |
| EP-1231938-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2002-08-21 | — | — | EP | disclosed |
| US-20020013370-A1 | Methods for identifying and treating resistant tumors | SAWYER JASON SCOTT (US) | 2002-01-31 | — | — | US | disclosed |
| US-20020010213-A1 | Methods for identifying and treating resistant tumors | SAWYER JASON SCOTT (US) | 2002-01-24 | — | — | US | disclosed |
| EP-1129707-A2 | Methods for identifying and treating resistant tumors | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2001-09-05 | — | — | EP | disclosed |
| EP-0743064-A1 | Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease | ELI LILLY AND COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| EP-0735870-A1 | USE OF PLA 2? INHIBITORS AS TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1996-10-09 | — | — | EP | disclosed |
| US-5563164-A | TREATING ARTHRITIS, PSORIASIS, ASTHMA, INFLAMMATORY BOWEL DISEASE, OR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| US-5543428-A | ADMINISTERING SUBSTITUTED PHENOXYALKYL COMPOUNDS TO REVERSE DRUG RESISTANCE | ELI LILLY AND COMPANY (US) | 1996-08-06 | — | — | US | disclosed |
| WO-1996006604-A2 | METHODS FOR IDENTIFYING AND TREATING RESISTANT TUMORS | ELI LILLY AND COMPANY (US) | 1996-03-07 | — | — | WO | disclosed |
| US-5478857-A | Administering inhibitor of phospholipase A2 | ELI LILLY AND COMPANY (US) | 1995-12-26 | — | — | US | disclosed |
| US-5462954-A | Antiinflammatory, antiallergens; treating asthma | ELI LILLY AND COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
| WO-1995017183-A1 | USE OF PLA2 INHIBITORS AS TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1995-06-29 | — | — | WO | disclosed |
| CN-1088906-A | The phenyl phenol leukotriene antagonists that replaces | LILLY CO ELI (US) | 1994-07-06 | — | — | CN | disclosed |
| EP-0544488-A2 | Substituted phenyl phenol leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1993-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013370-A1 | Methods for identifying and treating resistant tumors | ABCC1, SLC11A2, VHL | NR1H4 222/4885PTPN1 2971/4885LMNA 1418/4885 |
| US-20040198779-A1 | Heterocycle substituted diphenyl leukotriene antagonists | LTB4R, LTB4R2, LTA4H | NR1H4 233/4885PTPN1 2340/4885LMNA 2338/4885 |
| US-20020010213-A1 | Methods for identifying and treating resistant tumors | ABCC1, SLC11A2, VHL | NR1H4 222/4885PTPN1 2971/4885LMNA 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.